IntegraGen SA (ALINT.PA)

EUR 0.53

(0.0%)

EBITDA Summary of IntegraGen SA

  • IntegraGen SA's latest annual EBITDA in 2023 was -52.5 Thousand EUR , down -84.26% from previous year.
  • IntegraGen SA's latest quarterly EBITDA in 2024 Q2 was -97 Thousand EUR , down 0.0% from previous quarter.
  • IntegraGen SA reported an annual EBITDA of 69.96 Thousand EUR in 2022, down -47.98% from previous year.
  • IntegraGen SA reported an annual EBITDA of 96.45 Thousand EUR in 2021, up 226.5% from previous year.
  • IntegraGen SA reported a quarterly EBITDA of -321.1 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.
  • IntegraGen SA reported a quarterly EBITDA of N/A for 2023 FY, down -84.26% from previous quarter.

Annual EBITDA Chart of IntegraGen SA (2023 - 2008)

Historical Annual EBITDA of IntegraGen SA (2023 - 2008)

Year EBITDA EBITDA Growth
2023 -52.5 Thousand EUR -84.26%
2022 69.96 Thousand EUR -47.98%
2021 96.45 Thousand EUR 226.5%
2020 -235.89 Thousand EUR 177.16%
2019 -179.2 Thousand EUR 93.29%
2018 -1.19 Million EUR 42.25%
2017 -1.8 Million EUR -7.99%
2016 -1.67 Million EUR 24.81%
2015 -1.44 Million EUR -38.59%
2014 -1.6 Million EUR 42.91%
2013 -2.8 Million EUR -22.93%
2012 -2.31 Million EUR 8.76%
2011 -2.45 Million EUR 15.6%
2010 -3.47 Million EUR 10.78%
2009 -3.27 Million EUR -4.78%
2008 -3.21 Million EUR 0.0%

Peer EBITDA Comparison of IntegraGen SA

Name EBITDA EBITDA Difference
ABIONYX Pharma SA -3.29 Million EUR 98.404%
ABIVAX Société Anonyme -133.2 Million EUR 99.961%
Adocia SA -22.73 Million EUR 99.769%
Aelis Farma SA -6.34 Million EUR 99.173%
Biophytis S.A. -13.8 Million EUR 99.62%
Advicenne S.A. -6.24 Million EUR 99.159%
genOway Société anonyme 6.35 Million EUR 100.827%
Medesis Pharma S.A. -3.84 Million EUR 98.634%
Neovacs S.A. -8.44 Million EUR 99.379%
NFL Biosciences SA -4.04 Million EUR 98.703%
Plant Advanced Technologies SA 72.53 Thousand EUR 172.388%
Quantum Genomics Société Anonyme -2.87 Million EUR 98.173%
Sensorion SA -22.31 Million EUR 99.765%
Theranexus Société Anonyme -7.38 Million EUR 99.289%
TME Pharma N.V. -5.07 Million EUR 98.965%
Valbiotis SA -6.95 Million EUR 99.245%
TheraVet SA -517.33 Thousand EUR 89.851%
Valerio Therapeutics Société anonyme -18.91 Million EUR 99.722%
argenx SE -199.5 Million EUR 99.974%
BioSenic S.A. -6.79 Million EUR 99.227%
Celyad Oncology SA -7.76 Million EUR 99.324%
DBV Technologies S.A. -79.53 Million EUR 99.934%
Galapagos NV 51.03 Million EUR 100.103%
Genfit S.A. -28.05 Million EUR 99.813%
GeNeuro SA -14.31 Million EUR 99.633%
Hyloris Pharmaceuticals SA -14.98 Million EUR 99.65%
Innate Pharma S.A. -7.57 Million EUR 99.307%
Inventiva S.A. -101.84 Million EUR 99.948%
MaaT Pharma SA -19.74 Million EUR 99.734%
MedinCell S.A. -20.04 Million EUR 99.738%
Nanobiotix S.A. -34.01 Million EUR 99.846%
Onward Medical N.V. -35.23 Million EUR 99.851%
Oryzon Genomics S.A. -4.43 Million EUR 98.816%
OSE Immunotherapeutics SA -23.26 Million EUR 99.774%
Oxurion NV -16.72 Million EUR 99.686%
Pharming Group N.V. 4.98 Million EUR 101.054%
Poxel S.A. -12.17 Million EUR 99.569%
GenSight Biologics S.A. -21.73 Million EUR 99.758%
Transgene SA -27.02 Million EUR 99.806%
Financière de Tubize SA 184.57 Thousand EUR 128.446%
UCB SA 1.26 Billion EUR 100.004%
Valneva SE -64.51 Million EUR 99.919%
Vivoryon Therapeutics N.V. -28.35 Million EUR 99.815%